Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Denifanstat - Sagimet Biosciences

Next Previous
X
Search
Drug Profile

Denifanstat - Sagimet Biosciences

Alternative Names: ASC 40; TVB-2640

Latest Information Update: 26 Nov 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator 3-V Biosciences
  • Developer Ascletis; Mayo Clinic; Sagimet Biosciences; University of Kentucky; University of Texas Health Science Center at San Antonio
  • Class Antiacnes; Antineoplastics; Benzonitrile; Cyclobutanes; Hepatoprotectants; Piperidines; Skin disorder therapies; Small molecules; Triazoles
  • Mechanism of Action Fatty acid synthetase complex inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acne vulgaris; Glioblastoma
  • Phase II Astrocytoma; Breast cancer; Non-alcoholic steatohepatitis; Non-small cell lung cancer
  • Phase I Liver disorders; Prostate cancer
  • Preclinical Liver cancer
  • No development reported Colorectal cancer; Solid tumours

Most Recent Events

  • 18 Nov 2024 Updated efficacy data from the phase-IIb FASCINATE-2 trial in Non-alcoholic steatohepatitis released by Sagimet Biosciences
  • 18 Nov 2024 Ascletis Pharma completes enrolment in its phase III trial for Acne vulgaris in China in China (PO)
  • 14 Nov 2024 Sagimet Biosciences plans a phase III FASCINIT trial for Non-alcoholic steatohepatitis (PO) in December 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top